{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T01:14:17Z","timestamp":1767143657333,"version":"build-2238731810"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,2,4]],"date-time":"2017-02-04T00:00:00Z","timestamp":1486166400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s40618-016-0604-8","type":"journal-article","created":{"date-parts":[[2017,2,4]],"date-time":"2017-02-04T01:33:15Z","timestamp":1486171995000},"page":"669-678","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Long-term safety and efficacy of Omnitrope\u00ae in adults with growth hormone deficiency: Italian interim analysis of the PATRO Adults study"],"prefix":"10.1007","volume":"40","author":[{"given":"D.","family":"Ferone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Profka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Gasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. R.","family":"Ambrosio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Colao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Di Somma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Puxeddu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Arnaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Pagano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Zecchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Pietropoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Beck-Peccoz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,2,4]]},"reference":[{"issue":"6","key":"604_CR1","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1530\/EJE-07-0631","volume":"157","author":"KK Ho","year":"2007","unstructured":"Ho KK (2007) Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol 157(6):695\u2013700. doi: 10.1530\/EJE-07-0631","journal-title":"Eur J Endocrinol"},{"issue":"Suppl 3","key":"604_CR2","doi-asserted-by":"publisher","first-page":"S197","DOI":"10.4103\/2230-8210.84865","volume":"15","author":"V Gupta","year":"2011","unstructured":"Gupta V (2011) Adult growth hormone deficiency. Indian J Endocrinol Metab 15(Suppl 3):S197\u2013S202. doi: 10.4103\/2230-8210.84865","journal-title":"Indian J Endocrinol Metab"},{"issue":"6","key":"604_CR3","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1210\/jc.2011-0179","volume":"96","author":"ME Molitch","year":"2011","unstructured":"Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML (2011) Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96(6):1587\u20131609. doi: 10.1210\/jc.2011-0179","journal-title":"J Clin Endocrinol Metab"},{"key":"604_CR4","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3389\/fendo.2013.00064","volume":"4","author":"ML Reed","year":"2013","unstructured":"Reed ML, Merriam GR, Kargi AY (2013) Adult growth hormone deficiency\u2014benefits, side effects, and risks of growth hormone replacement. Front Endocrinol (Lausanne) 4:64. doi: 10.3389\/fendo.2013.00064","journal-title":"Front Endocrinol (Lausanne)"},{"key":"604_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-016-0951-4","author":"M Boschetti","year":"2016","unstructured":"Boschetti M, Agosti S, Albanese V, Casalino L, Teti C, Bezante GP, Brunelli C, Albertelli M, Ferone D (2016) One-year GH replacement therapy reduces early cardiac target organ damage (TOD) in adult GHD patients. Endocr. doi: 10.1007\/s12020-016-0951-4","journal-title":"Endocr"},{"key":"604_CR6","unstructured":"European Medicines Agency Guideline on similar biological medicinal products. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2014\/10\/WC500176768.pdf . Accessed 5 April 2016"},{"issue":"10","key":"604_CR7","first-page":"298","volume":"2","author":"K Thakrar","year":"2010","unstructured":"Thakrar K, Bodalia P, Grosso A (2010) Assessing the efficacy and safety of Omnitrope. Br J. Clin Pharm 2(10):298\u2013301","journal-title":"Br J. Clin Pharm"},{"key":"604_CR8","unstructured":"Ullah A, Peacock H, Arutchelvam V, Nag S, Ashwell S (2012) The cost, efficacy and safety of Omnitrope compared with Genotropin in adults with growth hormone deficiency. Presented at BES 2012; 18\u201322 March 2012; Harrogate, UK. Endocrine Abstracts 28:P52"},{"issue":"3","key":"604_CR9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1177\/2042018812444152","volume":"3","author":"P Beck-Peccoz","year":"2012","unstructured":"Beck-Peccoz P, Minuto F, Leal-Cerro A, Zabransky M, Stalla G (2012) Rationale and design of PATRO Adults, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope\u00ae for the treatment of adult patients with growth hormone deficiency. Ther Adv Endocrinol Metab 3(3):85\u201391. doi: 10.1177\/2042018812444152","journal-title":"Ther Adv Endocrinol Metab"},{"key":"604_CR10","doi-asserted-by":"crossref","unstructured":"Beck-Peccoz P, H\u00f6ybye C, Murray RD, Simsek S, Leal-Cerro A, Zabransky M, Stalla G (2015) The PATRO adult study of Omnitrope\u00ae for the treatment of adult patients with GH deficiency: latest results [abstract]. Presented at the 17th European Congress of Endocrinology (ESE 2015); 16\u201320 May 2015; Dublin, Ireland. Endocrine Abstracts 37:EP665","DOI":"10.1530\/endoabs.37.EP665"},{"key":"604_CR11","unstructured":"Stalla G, Leal-Cerro A, Simsek S, Minuto F, Zabransky M, Beck-Peccoz P (2013) First results from the PATRO adults study of omnitrope for the treatment of adult patients with GH deficiency [abstract]. Presented at the 15th European Congress of Endocrinology (ECE 2013); April 27-May 1, 2013; Copenhagen, Denmark. Endocrine Abstracts 32:P630"},{"key":"604_CR12","unstructured":"Beck-Peccoz P, H\u00f6ybye C, Murray RD, Simsek S, Leal-Cerro A, Minuto F, Zabransky M, Stalla G (2014) The PATRO Adults study of Omnitrope\u00ae for the treatment of adult patients with growth hormone deficiency: latest results [abstract]. Presented at the 16th International Congress of Endocrinology and the Endocrine Society\u2019s 96th Annual Meeting & Expo (ICE\/ENDO 2014); 21\u201324 June 2014; Chicago, IL, USA. Poster SAT-0693"},{"key":"604_CR13","unstructured":"European Medicines Agency (2011) Omnitrope\u00ae summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000607\/WC500043695.pdf . Accessed 19 Nov 2015."},{"issue":"1","key":"604_CR14","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1210\/jc.2009-1326","volume":"95","author":"AF Attanasio","year":"2010","unstructured":"Attanasio AF, Mo D, Erfurth EM, Tan M, Ho KY, Kleinberg D, Zimmermann AG, Chanson P (2010) Prevalence of metabolic syndrome in adult hypopituitary growth hormone (GH)-deficient patients before and after GH replacement. J Clin Endocrinol Metab 95(1):74\u201381. doi: 10.1210\/jc.2009-1326","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"604_CR15","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1530\/EJE-11-0599","volume":"165","author":"J Verhelst","year":"2011","unstructured":"Verhelst J, Mattsson AF, Luger A, Thunander M, G\u00f3th MI, Koltowska-H\u00e4ggstr\u00f6m M, Abs R (2011) Prevalence and characteristics of the metabolic syndrome in 2479 hypopituitary patients with adult-onset GH deficiency before GH replacement: a KIMS analysis. Eur J Endocrinol 165(6):881\u2013889. doi: 10.1530\/EJE-11-0599","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"604_CR16","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1210\/jc.2011-0448","volume":"96","author":"AF Attanasio","year":"2011","unstructured":"Attanasio AF, Jung H, Mo D, Chanson P, Bouillon R, Ho KK, Lamberts SW, Clemmons DR (2011) Prevalence and incidence of diabetes mellitus in adult patients on growth hormone replacement for growth hormone deficiency: a surveillance database analysis. J Clin Endocrinol Metab 96(7):2255\u20132261. doi: 10.1210\/jc.2011-0448","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"604_CR17","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1210\/jc.2012-2940","volume":"98","author":"KM Claessen","year":"2013","unstructured":"Claessen KM, Appelman-Dijkstra NM, Adoptie DM, Roelfsema F, Smit JW, Biermasz NR, Pereira AM (2013) Metabolic profile in growth hormone-deficient (GHD) adults after long-term recombinant human growth hormone (rhGH) therapy. J Clin Endocrinol Metab 98(1):352\u2013361. doi: 10.1210\/jc.2012-2940","journal-title":"J Clin Endocrinol Metab"},{"issue":"9204","key":"604_CR18","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/S0140-6736(99)04055-6","volume":"355","author":"WS Cutfield","year":"2000","unstructured":"Cutfield WS, Wilton P, Bennmarker H, Albertsson-Wikland K, Chatelain P, Ranke MB, Price DA (2000) Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment. The Lancet 355(9204):610\u2013613. doi: 10.1016\/S0140-6736(99)04055-6","journal-title":"The Lancet"},{"issue":"4","key":"604_CR19","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s40618-014-0196-0","volume":"38","author":"E Profka","year":"2015","unstructured":"Profka E, Giavoli C, Bergamaschi S, Ferrante E, Malchiodi E, Sala E, Verrua E, Rodari G, Filopanti M, Beck-Peccoz P, Spada A (2015) Analysis of short- and long-term metabolic effects of growth hormone replacement therapy in adult patients with craniopharyngioma and non-functioning pituitary adenoma. J Endocrinol Invest 38(4):413\u2013420. doi: 10.1007\/s40618-014-0196-0","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"604_CR20","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1210\/jcem.87.5.8482","volume":"87","author":"J Svensson","year":"2002","unstructured":"Svensson J, Fowelin J, Landin K, Bengtsson BA, Johansson JO (2002) Effects of seven years of GH-replacement therapy on insulin sensitivity in GH-deficient adults. J Clin Endocrinol Metab 87(5):2121\u20132127. doi: 10.1210\/jcem.87.5.8482","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"604_CR21","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1530\/eje.0.1460807","volume":"146","author":"AG Hatrick","year":"2002","unstructured":"Hatrick AG, Boghalo P, Bingham JB, Ayres AB, Sonksen PH, Russell-Jones DL (2002) Does GH replacement therapy in adult GH-deficient patients result in recurrence or increase in size of pituitary tumours? Eur J Endocrinol 146(6):807\u2013811","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"604_CR22","doi-asserted-by":"publisher","first-page":"5172","DOI":"10.1210\/jcem.86.11.8018","volume":"86","author":"G Frajese","year":"2001","unstructured":"Frajese G, Drake WM, Loureiro RA, Evanson J, Coyte D, Wood DF, Grossman AB, Besser GM, Monson JP (2001) Hypothalamo-pituitary surveillance imaging in hypopituitary patients receiving long-term GH replacement therapy. J Clin Endocrinol Metab 86(11):5172\u20135175. doi: 10.1210\/jcem.86.11.8018","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"604_CR23","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1530\/EJE-07-0164","volume":"157","author":"M Buchfelder","year":"2007","unstructured":"Buchfelder M, Kann PH, W\u00fcster C, Tuschy U, Saller B, Brabant G, Kleindienst A, Nomikos P (2007) Influence of GH substitution therapy in deficient adults on the recurrence rate of hormonally inactive pituitary adenomas: a case control study. Eur J Endocrinol 157(2):149\u2013156. doi: 10.1530\/EJE-07-0164","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"604_CR24","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1530\/EJE-11-0286","volume":"165","author":"CJ Child","year":"2011","unstructured":"Child CJ, Zimmermann AG, Woodmansee WW, Green DM, Li JJ, Jung H, Erfurth EM, Robison LL (2011) Assessment of primary cancers in GH-treated adult hypopituitary patients: an analysis from the Hypopituitary Control and Complications Study. Eur J Endocrinol 165(2):217\u2013223. doi: 10.1530\/EJE-11-0286","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"604_CR25","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s40618-014-0179-1","volume":"38","author":"E Brignardello","year":"2015","unstructured":"Brignardello E, Felicetti F, Castiglione A, Fortunati N, Matarazzo P, Biasin E, Sacerdote C, Ricardi U, Fagioli F, Corrias A, Arvat E (2015) GH replacement therapy and second neoplasms in adult survivors of childhood cancer: a retrospective study from a single institution. J Endocrinol Invest 38(2):171\u2013176. doi: 10.1007\/s40618-014-0179-1","journal-title":"J Endocrinol Invest"},{"key":"604_CR26","doi-asserted-by":"crossref","unstructured":"Stalla G, Beck-Peccoz P, Hoybye C, Murray RD, Simsek S, Leal-Cerro A, Zabransky M. The PATRO Adults study of Omnitrope\u00ae for the treatment of adult patients with growth hormone deficiency: latest results. Presented at the 2016 Endocrine Societie\u2019s Annual Meeting (ENDO 2016); 1\u20134 April 2016; Boston, MA, USA","DOI":"10.1530\/endoabs.41.GP128"}],"updated-by":[{"DOI":"10.1007\/s40618-017-0664-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2017,4,18]],"date-time":"2017-04-18T00:00:00Z","timestamp":1492473600000}}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40618-016-0604-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-016-0604-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-016-0604-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T03:45:16Z","timestamp":1568778316000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40618-016-0604-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,4]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["604"],"URL":"https:\/\/doi.org\/10.1007\/s40618-016-0604-8","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,4]]}}}